Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods

作者: Michael E. Klepser , Erika J. Ernst , Russell E. Lewis , Michael E. Ernst , Michael A. Pfaller

DOI: 10.1128/AAC.42.5.1207

关键词: Candida tropicalisFluconazoleMinimum inhibitory concentrationAmphotericin BMicrobiologyCandida glabrataFungi imperfectiBiologyCandida albicansLiterChromatography

摘要: This study was designed to examine the effects of antifungal carryover, agitation, and starting inoculum on results time-kill tests conducted with various Candida species. Two isolates each albicans, tropicalis, glabrata were utilized. Test agents included fluconazole, amphotericin B, LY303366. Time-kill in RPMI 1640 medium buffered morpholinepropanesulfonic acid (MOPS) a pH 7.0 incubated at 35°C. Prior testing, existence carryover evaluated concentrations ranging from 1× 16× MIC by four plating methods: direct 10, 30, 100 μl test suspension filtration 30 through 0.45-μm-pore-size filter. curves performed isolate drug equal 2× MIC, using approximately 105 CFU/ml, or without agitation. Last, experiments over three ranges inocula: 5 × 102 1 104, >1 104 106, 106 108 CFU/ml. Significant (>25% reduction CFU/milliliter control value) observed B fluconazole; however, eliminated filtration. Agitation did not appreciably affect results. The significantly activity fluconazole B; LY303366 may be influenced inoculum. Before curve methods are routinely employed investigators, methodology should scrutinized standardized procedures developed.

参考文章(9)
Erika Bruck, National Committee for Clinical Laboratory Standards. Pediatrics. ,vol. 65, pp. 187- 188 ,(1980)
Michael E. Ernst, Michael E. Klepser, Erika J. Wolfe, Michael A. Pfaller, Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagnostic Microbiology and Infectious Disease. ,vol. 26, pp. 125- 131 ,(1996) , 10.1016/S0732-8893(96)00202-7
R D Pearson, R T Steigbigel, H T Davis, S W Chapman, Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrobial Agents and Chemotherapy. ,vol. 18, pp. 699- 708 ,(1980) , 10.1128/AAC.18.5.699
Michael E. Klepser, Erika J. Ernst, Michael E. Ernst, Michael A. Pfaller, Growth medium effect on the antifungal activity of LY 303366 Diagnostic Microbiology and Infectious Disease. ,vol. 29, pp. 227- 231 ,(1997) , 10.1016/S0732-8893(97)00144-2
M E Klepser, E J Wolfe, R N Jones, C H Nightingale, M A Pfaller, Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 1392- 1395 ,(1997) , 10.1128/AAC.41.6.1392
J. H. Rex, M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, , Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections Clinical Infectious Diseases. ,vol. 24, pp. 235- 249 ,(1997) , 10.1093/CLINIDS/24.2.235
M. E. Klepser, E. J. Wolfe, M. A. Pfaller, Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy. ,vol. 41, pp. 397- 401 ,(1998) , 10.1093/JAC/41.3.397
Russell E. Lewis, Brian C. Lund, Michael E. Klepser, Erika J. Ernst, Michael A. Pfaller, Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 1382- 1386 ,(1998) , 10.1128/AAC.42.6.1382
M A Pfaller, S A Messer, S Coffman, In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 763- 766 ,(1997) , 10.1128/AAC.41.4.763